Publications by authors named "L Y Dirix"
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.
View Article and Find Full Text PDFMolecular characterization of the histopathological growth patterns of colorectal cancer liver metastases by RNA sequencing of targeted samples at the tumor-liver interface.
Clin Exp Metastasis
December 2024
Article Synopsis
- Metastatic behavior in liver-metastatic colorectal cancer (CRC) varies significantly based on histopathological growth patterns (HGPs), influencing treatment outcomes, with desmoplastic HGP being linked to favorable and replacement HGP to unfavorable outcomes.
- Understanding cellular and molecular factors of these growth patterns is crucial for improving cancer biology knowledge and designing effective clinical trials.
- Analysis of tumor tissue reveals that HGPs are influenced by epigenetic factors rather than specific gene mutations, with distinct gene expression differences reflecting cancer biology themes, such as inflammation for desmoplastic and cell proliferation for replacement patterns.
Metastatic breast cancer (mBC) remains incurable and liver metastases (LM) are observed in approximately 50% of all patients with mBC. In some cases, surgical resection of breast cancer liver metastases (BCLM) is associated with prolonged survival. However, there are currently no validated marker to identify these patients.
View Article and Find Full Text PDFObjective: To assess the expression pattern of X-linked inhibitor of apoptosis protein (XIAP), a cellular stress sensor, and delineate the associated changes in the tumor immune microenvironment (TiME) for prognostic value and new therapeutic targets in inflammatory breast cancer (IBC).
Methods: Immunohistochemistry was conducted to assess the spatial localization of immune subsets, XIAP, and PDL1 expression in IBC and non-inflammatory breast cancer (nIBC) pretreatment tumors (n = 142). Validation and further exploration were performed by gene expression analysis of patient tumors along with signaling studies in a co-culture model.